Leo J. Philip Tharappel

Leo J. Philip Tharappel

Auto-generated profile, based on publicly available information

Leo J. Philip Tharappel

Global Scientific Communications, Eli Lilly and Company, Indianapolis, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal of Complementary and Integrative Medicine
Verified
Journal Article
Closed access
SBSiddhi Bagwe
Siddhi Bagwe
LTLeo J.P. Tharappel
Leo J.P. Tharappel
GKGinpreet Kaur
Ginpreet Kaur
HBHarpal S. Buttar
Harpal S. Buttar
Nutraceutical, a term combining the words “nutrition” and “pharmaceuticals”, is a food or food product that provides health benefits as an adjuvant or alternative therapy, including the treatment and prevention of infectious diseases in children and adults. There is emerging evidence that bovine colostrum (BC) may be one of the promising nutraceuticals which can prevent or mitigate various diseases in newborns and adults. Immunity-related disorders are one of the leading causes of mortality in the world. BC is rich in immunity, growth and antimicrobial factors, which promote tissue growth and the maturation of digestive tract and immune function in neonatal animals and humans. The immunoglobulins and lactoferrin present in colostrum are known to build natural immunity in newborns which helps to reduce the mortality rate in this population. Also, the side-effect profile of colostrum proteins and possible lactose intolerance is relatively less in comparison with milk. In general, BC is considered safe and well tolerated. Since colostrum has several important nutritional constituents, well-designed, double-blind, placebo-controlled studies with colostrum products should be conducted to widen its therapeutic use. The objectives of this review are to create awareness about the nutraceutical properties of colostrum and to discuss the various ongoing alternative treatments of colostrum and its active ingredients as well as to address colostrum’s future nutraceutical and therapeutic implications in humans.

14 July 2026 in Pain and Therapy
Verified
Journal Article
Open access
SOSatomi Ooba
Satomi Ooba
DDDaisuke Danno
Daisuke Danno
RIRyotaro Ishii
Ryotaro Ishii
TTTsubasa Takizawa
Tsubasa Takizawa
MMMoemi Miura
Moemi Miura
CHChie Hashimoto
Chie Hashimoto
The burden of migraine on an individual's life is associated with an individual's background. However, limited evidence in Japan exists on the association of age, sex, employment, income, and family caregiving with patient-reported outcomes (PROs) and migraine treatment patterns. This analysis of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) 2nd study describes the migraine burden and treatment usage of individuals with migraine across these demographic subgroups. Participants self-reported demographic and clinical characteristics, and PRO instrument responses, such as Headache Impact Test-6, Migraine Disability Assessment Scale (MIDAS), Migraine-Specific Quality of Life Questionnaire version 2.1, Migraine Interictal Burden Scale-4 (MIBS-4), and Impact of Migraine on Partners and Adolescent Children Scale. They also reported use of over-the-counter and prescription drugs for migraine, and headache-related expenses. Descriptive statistics were reported according to sex, employment status, menstrual-related migraine status and frequency, annual personal and family income, age, and family caregiving status for the elderly. Female sex, unemployment, presence of menstrual-related migraine, low personal or family income, and family caregiving for elders appeared to increase migraine burden and impact prescription drug use. Specifically, men tended to have higher triptan (11.7% vs. 8.7%) and preventive medication use (18.3% vs. 11.2%) than women; unemployed women had the highest proportion of MIDAS grade IV (14.1%); women with menstrual-related migraine appeared to have greater MIBS-4 severe burden (36.3% vs. 27.8%) than those without; and family caregivers tended to have higher MIBS-4 severe burden (39.2% vs. 26.0%) and prescription drug use than non-caregivers. Respondent sex further appeared to influence migraine burden and treatment patterns within the employment and income subgroups. These data suggest certain sociodemographic groups may suffer from greater migraine burden and have reduced access to effective treatment and care. We hope this study's results will help healthcare providers and societies identify such populations with migraine and address potential clinical care gaps.

15 September 2015 in International Journal of Cancer Research
Verified
Journal Article
Closed access
LTLeo J.P. Tharappel
Leo J.P. Tharappel
PPParmi Patel
Parmi Patel
GKGinpreet Kaur
Ginpreet Kaur
VAVeeranjaneyulu Addepalli
Veeranjaneyulu Addepalli